Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 3/20 | 0.59 |
| ▸ | ACACB | O00763 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.33 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.30 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL707622 | 0.93 | ALOX5AP (0.63) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL709308 | 0.93 | ALOX5AP (0.63) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL2999090 | 0.90 | ALOX5AP (0.48) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL3000902 | 0.86 | ALOX5AP (0.43) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL2995111 | 0.83 | ALOX5AP (0.43) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL2997435 | 0.81 | ALOX5AP (0.86) | ALOX5APNPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2998243 | 0.81 | ALOX5AP (0.41) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL3002980 | 0.78 | APP (0.45) | ALOX5APACACBMMP9MMP13ADAM17 | |
| SCHEMBL2995463 | 0.77 | AOC3 (0.39) | ALOX5APACACBMAPTFFAR1PPARD | |
| SCHEMBL706833 | 0.77 | ALOX5AP (0.72) | ALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | claimed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | claimed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | claimed |
| EP-2546232-A1 | Diphenyl Substituted Alkanes | Merck Sharp & Dohme Corp. (US) | 2013-01-16 | — | — | EP | disclosed |
| US-7786304-B2 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2010-08-31 | — | — | US | disclosed |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK SHARP & DOHME CORP. | 2010-07-29 | — | — | US | disclosed |
| EP-2170065-A1 | DIPHENYL SUBSTITUTED ALKANES | Merck Sharp & Dohme Corp. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008156721-A1 | DIPHENYL SUBSTITUTED ALKANES | MERCK & CO., INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080146800-A1 | Process for the preparation of eszopiclone | CENTAUR PHARMACEUTICAL PVT. LTD. (IN) | 2008-06-19 | — | — | US | disclosed |
| EP-0855398-B1 | SESQUITERPENE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-5876984-A | OBTAINED BY CULTURING MICROORGANISM OF STACHYBOTRYS GENUS | SHIONOGI & CO., LTD (JP) | 1999-03-02 | — | — | US | disclosed |
| EP-0855398-A1 | SESQUITERPENE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 1998-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146800-A1 | Process for the preparation of eszopiclone | CYP3A5, CYP3A7, CYP51A1 | ALOX5AP 377/4885ACACB 3628/4885MMP9 1759/4885 |
| US-20100190761-A1 | DIPHENYL SUBSTITUTED ALKANES | ALOX5, ALOX15, ALOX15B | ALOX5AP 15/4885ACACB 1284/4885MMP9 793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.